Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

NCT05579977 · Terminated

Last updated 2026-05-28

This clinical trial is testing the study medicine PF-07081532, either alone or combined with Rybelsus, in adults with type 2 diabetes and PF-07081532 alone in adults with obesity to see how it affects blood sugar levels.

Status Terminated Stopped early and will not restart.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 902 people

Who can join Ages 18–75 · all sexes

Timeline Started 2022-10 · est. completion 2023-09

Where 90 sites · Bulgaria, Canada, Czechia, Hungary, Japan, Poland, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT05579977 ↗

Description as written by the study sponsor.

The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.

Treatments tested

PF-07081532 Drug

Oral glucagon-like peptide-1 receptor agonist
Placebo Other

No drug
Rybelsus Drug

Oral Semaglutide

Main thing measured	Placebo-adjusted, Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c) at Week 32: Cohort 1 (Type 2 Diabetes Mellitus)
Sponsor	Pfizer
Conditions studied	Diabetes Mellitus, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05579977 ↗